Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,383 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,383 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06500377 | Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer… | N/A | suspended | Jul 15, 2024 | City of Hope Medical Center | Accrual Goal Met | Enrollment / accrual |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With… | Phase 2 | withdrawn | Feb 17, 2026 | Memorial Sloan Kettering Cancer Center | The sponsor is no longer supporting the trial because they are no longer interested in studying the… | Other (stated, no rule matched) |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | Phase 4 | terminated | Jan 26, 2023 | University of Colorado, Denver | Study completed | Other (stated, no rule matched) |
| NCT05930496 | Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III… | N/A | terminated | Jul 5, 2023 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… | Phase 2 | terminated | Mar 27, 2024 | Memorial Sloan Kettering Cancer Center | Study closed by Amgen due to lack of enrollment | Enrollment / accrual |
| NCT06487377 | IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced… | Phase 1 | withdrawn | Jul 5, 2024 | Shanghai Pudong Hospital | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT06581211 | Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy… | N/A | suspended | Sep 3, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | Phase 3 | suspended | Nov 4, 2024 | Alliance for Clinical Trials in Oncology | Amending protocol to increase sample size | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT06895681 | UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations | — | withdrawn | Mar 26, 2025 | University of California, San Francisco | IRB study closure | Other (stated, no rule matched) |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Phase 1 | suspended | Mar 15, 2022 | CStone Pharmaceuticals | The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term… | Other (stated, no rule matched) |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or…(PINNACLE) | Phase 3 | suspended | May 18, 2022 | Spectrum Pharmaceuticals, Inc | The study has not enrolled any patients. The study design is under discussion and will likely be… | Enrollment / accrual |
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | Early Phase 1 | terminated | Jun 30, 2022 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co.,… | Sponsor / business decision |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT02625961 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in… | Phase 2 | terminated | Dec 9, 2015 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05458960 | Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate(BASICS) | N/A | terminated | Jul 14, 2022 | Washington University School of Medicine | Staffing issues | Other (stated, no rule matched) |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 6, 2023 | Roswell Park Cancer Institute | Funding ended | Funding |
| NCT06438588 | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on… | N/A | terminated | Jun 3, 2024 | Mayo Clinic | Low accrual | Enrollment / accrual |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically… | Phase 2 | withdrawn | May 25, 2025 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in… | Phase 2 | suspended | Jun 29, 2025 | National Cancer Institute (NCI) | Other - planned analysis of safety and efficacy data | Safety / toxicity |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408… | Phase 1 | terminated | Jul 22, 2025 | Alpha-9 Oncology USA Inc. | Due to a strategic decision to re-prioritize the sponsor's existing portfolio. | Sponsor / business decision |
| NCT06804785 | Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer…(HIT-PIRADS) | — | withdrawn | Feb 3, 2025 | Northwestern University | Due to funding issues the study did not move forward with prospective enrollment | Enrollment / accrual |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT07488884 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept,…(ResQ108B-PANC) | Phase 1 | withdrawn | Mar 23, 2026 | ImmunityBio, Inc. | The sponsor has changed the development plans which is not for safety reasons. | Safety / toxicity |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… | Phase 2 | suspended | Jun 10, 2026 | UNC Lineberger Comprehensive Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT04669860 | Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate… | — | suspended | Dec 17, 2020 | University of Miami | lack of funding | Funding |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in… | Phase 1 | terminated | Oct 23, 2023 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT06235671 | Effects of Chiropractic on Chronic Cancer-related Fatigue(CAN) | N/A | withdrawn | Feb 1, 2024 | Life University | Budget constraints | Funding |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy… | Phase 2 | terminated | Mar 25, 2008 | Hoffmann-La Roche | not stated | Not stated |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | N/A | suspended | Dec 14, 2016 | M.D. Anderson Cancer Center | Accrual Limit | Enrollment / accrual |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic… | Phase 2 | terminated | Feb 22, 2018 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer… | Phase 1 / Phase 2 | terminated | Nov 17, 2020 | Amgen | Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not… | Safety / toxicity |
| NCT07338357 | Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | Early Phase 1 | withdrawn | Jan 13, 2026 | First Affiliated Hospital of Guangxi Medical University | Strategic adjustment. | Sponsor / business decision |
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Phase 1 | suspended | Feb 5, 2026 | National Cancer Institute (NCI) | New recruitment on hold for a protocol design amendment/modification. | Enrollment / accrual |
| NCT01216371 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant…(SMAT) | Phase 2 | terminated | Oct 7, 2010 | Association of Urologic Oncology (AUO) | not stated | Not stated |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | Early Phase 1 | terminated | Oct 23, 2020 | Koo Foundation Sun Yat-Sen Cancer Center | The decision has been made to terminate the study due to logistical reasons and not due to any… | Safety / toxicity |
| NCT06514261 | Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs… | Phase 1 | suspended | Jul 23, 2024 | National Cancer Institute (NCI) | Other - Pending amendment for study expansion. | Other (stated, no rule matched) |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | Phase 1 | terminated | May 30, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03184753 | Genetically Modified T Cells Against Ovarian Cancer | Phase 1 / Phase 2 | terminated | Jun 14, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03185468 | Intervention of Bladder Cancer by CAR-T | Phase 1 / Phase 2 | terminated | Jun 14, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Nov 29, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03535246 | Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | Phase 1 / Phase 2 | terminated | May 24, 2018 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | Phase 1 / Phase 2 | terminated | Jul 8, 2019 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04085159 | Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis… | Phase 1 / Phase 2 | terminated | Sep 11, 2019 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | Phase 1 | terminated | Mar 2, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 3, 2026source: clinicaltrials